Regeneron Q1 Results: EYLEA HD Growth Continues, Franchise Stabilization Unproven

What happened

Regeneron reported Q1 2026 financials, with EYLEA HD net sales increasing sequentially, but total EYLEA franchise dollars remain pressured by 2mg erosion and biosimilar competition. Dupixent profit-share from Sanofi provided a reliable earnings backstop, but the critical question remains whether HD growth can fully offset legacy declines. Management reiterated expectations for a Q2 2026 FDA decision on the pre-filled syringe, a key catalyst to reduce office friction. However, the DeepValue report's margin of safety analysis highlights that without clear franchise stabilization, the current 17.7x P/E offers limited downside protection. The Q1 data are incrementally positive but do not yet confirm the base-case scenario of sustained mid-single-digit HD quarterly growth.

Implication

The investment thesis hinges on HD growth trajectory and the PFS catalyst; Q1 results are supportive but insufficient to shift the base case $830 target. Attractive entry remains near $720, with reassessment after Q2 or PFS decision.

Thesis delta

Q1 results provide modest support for the HD adoption thesis, but the lack of explicit franchise dollar stabilization keeps the risk-reward balanced. The key catalyst remains the PFS decision in Q2, and until then, the stock may trade sideways within the $720–$830 range.